| 1 |
邵为朋，王晓伟，刘德若. 小细胞肺癌目前治疗的策略与未来方向[J]. 中国肺癌杂志，2017, 20(6): 421-426.
|
| 2 |
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919.
|
| 3 |
Carbone DP, Reck M, Pazares L, et al. First-line nivolumab in stage Ⅳ or recurrent non-small-cell lung cancer.[J]. N Engl J Med, 2017, 39(25): 2415-2426.
|
| 4 |
朱以香，李峻岭. 广泛期小细胞肺癌的维持治疗研究进展[J]. 癌症进展，2017, 15(9): 990-993.
|
| 5 |
陈 杰. 病理诊断免疫组化手册[M]. 中国协和医科大学出版社，2014：56-67.
|
| 6 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 7 |
孔凡豹，刘 婷. 中央型小细胞肺癌CT影像与中医辨证分型相关性研究[J]. 辽宁中医药大学学报，2017, 11(10): 193-196.
|
| 8 |
Tanoue LT. Staging of Non-small cell lung cancer[J]. Semin Respir Crit Care Med, 2018, 29(3): 1-10.
|
| 9 |
高 盼，何文杰，孙英丽，等. 小细胞肺癌的CT表现分类及其价值[J]. 放射学实践，2018, 33(8): 847-851.
|
| 10 |
张全中，鲁 际. 多层螺旋CT在鉴别诊断小细胞肺癌与肺鳞癌中的应用[J]. 解放军医药杂志，2017, 29(12): 21-24.
|
| 11 |
肖永鑫，于 红，刘士远. 周围型小细胞肺癌的CT征象分析[J]. 实用放射学杂志，2017, 33(4): 4.
|
| 12 |
Brahmer JR, Govindan R, Anders RA, et al. The Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)[J]. J Immunother Cancer, 2018, 6(1): 75-81.
|
| 13 |
Sun Y, Hu B, Wang Q, et al. Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a[J]. Cell Death & Disease, 2018, 9(2): 85-89.
|
| 14 |
Cheng-gang, Meng-fan, Chun-zhu, et al. MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1[J]. Acta Pharm Sinica, 2017, 38(1): 110-119.
|
| 15 |
张亦飞，田东波，廖小雯，等. 肺腺癌和小细胞肺癌患者胸部CT征象及免疫组化特征分析[J]. 中国全科医学，2017, 20(z2): 138-140.
|
| 16 |
杨长俊. 小细胞肺癌患者CT扫描和癌组织Syn、CgA表达水平检测的临床意义[J]. 中国CT和MRI杂志，2018, 16(9): 14-17+157.
|
| 17 |
肖永鑫，于 红，刘士远，等. 周围型小细胞肺癌支气管血管束异常的CT表现[J]. 实用放射学杂志，2017, 12(11): 1674.
|
| 18 |
肖永鑫，于 红，刘士远，等. PET/CT在小细胞肺癌分期与治疗中的价值[J]. 中国医学影像技术，2017, 33(9): 1412-1416.
|
| 19 |
Herzberg B, Campo MJ, Gainor JF. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer[J]. Oncologist, 2017, 22(1): 81-88.
|
| 20 |
李宇婷，张慧芬，郑祥武，等. 小细胞肺癌的多层螺旋CT征象分析[J]. 医学研究杂志，2017, 46(1): 39-42.
|
| 21 |
Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study[J]. J Clin Oncol, 2019, 37(28): 2518-2527.
|
| 22 |
Rossi G, Bauckneht M, Genova C，et al. Comparison between 18F-FDG PET-based and CT-based criteria in non-small cell lung cancer patients treated with nivolumab[J]. J Nucl Med, 2020, 61(7): 990-998.
|
| 23 |
Zhang J, Zhao X, Zhao Y, et al. Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47(5): 1137-1146.
|
| 24 |
Wang Y, Zhao N, Wu Z, et al. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47(5): 1127-1136.
|
| 25 |
Castello A, Rossi S, Mazziotti E, et al. Hyperprogressive disease in patients with non-small cell lung cancer treated with checkpoint Inhibitors: The Role of 18F-FDG PET/CT[J]. J Nucl Med, 2020, 61(6): 821-826.
|
| 26 |
Xing Y, Chand G, Liu C, et al. Early phase I study of a 99mTc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer[J]. J Nucl Med, 2019, 60(9): 1213-1220.
|